These are good points. One question I have is since all the leronlimab cancer data is open label in stage 4 mestatic disease, outside of dosing, does it matter if the trial is open or closed with right to try as long as we are still getting progression and survival data from the patient's doctors. If significant improvement is noted compared to average for standard of care including troglevy, maybe that still can be used to file for BTD?